Skip to main content

Table 1 Improvements in JIA with adalimumab therapy

From: 7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis

 

AJC*

LOM**

PaP†

CHAQ DI‡

PhDA†

Baseline

17

14

49

1.05

57

Improvement at Week 56 of OLE

90%

70%

74%

83%

84%

  1. *75 joints assessed, **69 joints assessed
  2. †100-mm visual analog scale: greater scores = more active disease/more pain; ‡0 (best) to 3 (worst)